# Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

> **NCT02978183** · PHASE2 · COMPLETED · sponsor: **Noveome Biotherapeutics, formerly Stemnion** · enrollment: 70 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **BIOLOGICAL:** ST266
- **DRUG:** Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT02978183
- **Lead sponsor:** Noveome Biotherapeutics, formerly Stemnion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2017-02
- **Final completion:** 2017-11
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02978183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02978183, "Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02978183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*